Psychotic Disorders - France | Statista Market Forecast

Revenue in the Psychotic Disorders market is projected to reach US$204.40m in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 0.17%, resulting in a market volume of US$206.20m by 2029.
In global comparison, most revenue will be generated United States (US$2.26bn in 2024).
In relation to total population figures, per person revenues of US$243.70 are generated in 2024.

Psychotic disorders are severe mental health disorders that cause changes in a person's way of thinking and their perception. Patients often have trouble differentiating between what they perceive and reality. Different types of psychotic disorders include schizophrenia, bipolar disorder, substance-induced psychotic disorder, delusional disorder, and brief psychotic disorder. However, this market only represents the sales of antipsychotic drugs that are used to treat schizophrenia and bipolar disorder.

Market values represent the revenues generated by manufacturers and are based on retail prices for each drug category including all drugs, regardless of whether they are reimbursed or not.

Company examples: Otsuka Pharmaceutical, Lundbeck, AbbVie, Allergan plc, Recordati S.p.A., Gadeon Richter, Sumitomo Pharma, Johnson & Johnson / Janssen, Vanda Pharmaceuticals, Alkermes, Eli Lilly, AstraZeneca, and Intra-Cellular Therapies

Antipsychotic drugs: Aripiprazole (Abilify), Asenapine (Saphris), Cariprazine (Vraylar), Clozapine (Clozaril, Versacloz), lumateperone (Caplyta), Lurasidone (Latuda), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal), Risperidone (Aristada), Ziprasidone (Geodon), Brexpiprazole (Rexulti), Iloperidone (Fanapt), and Paliperidone (Invega)

Psychotherapy
Talk therapy
Herbal medicines
Digital health apps
Deep Brain Stimulation (DBS)

The Psychotic Disorders market in France is experiencing significant growth and development. Customer preferences are shifting towards more personalized and effective treatment options, leading to increased demand for innovative therapies. Additionally, local special circumstances and underlying macroeconomic factors are contributing to the market's expansion.Customer preferences in the Psychotic Disorders market in France are evolving, with a focus on personalized treatment options. Patients are increasingly seeking tailored therapies that address their specific symptoms and needs. This trend is driven by a growing awareness of the diverse nature of psychotic disorders and the recognition that individualized treatment approaches can lead to better outcomes. As a result, there is a rising demand for innovative medications and therapies that can effectively target the underlying causes of psychotic disorders.In addition to personalized treatment options, there is a growing preference for non-pharmacological interventions in the Psychotic Disorders market in France. Patients are increasingly interested in complementary therapies such as cognitive behavioral therapy, art therapy, and mindfulness-based interventions. These approaches are seen as holistic and effective in managing symptoms and improving overall well-being. As a result, healthcare providers are incorporating these therapies into their treatment plans, leading to increased demand for related services and products.The market is also witnessing a shift towards early intervention and prevention strategies. There is a growing recognition of the importance of early detection and treatment in managing psychotic disorders. Healthcare providers and policymakers in France are placing greater emphasis on early intervention programs, including screening initiatives and community-based mental health services. This focus on prevention is driving the demand for diagnostic tools, screening tests, and early intervention programs in the market.Local special circumstances in France are contributing to the growth of the Psychotic Disorders market. The country has a well-developed healthcare system that provides access to comprehensive mental health services. The government has implemented policies and initiatives to improve mental health care, including increased funding for psychiatric services and the integration of mental health into primary care. These efforts have increased awareness and access to treatment for psychotic disorders, driving market growth.Underlying macroeconomic factors are also influencing the development of the Psychotic Disorders market in France. The country has a stable economy and a high standard of living, which allows for increased healthcare spending. The government's commitment to mental health care and the availability of public and private health insurance coverage contribute to the affordability and accessibility of treatments for psychotic disorders. These favorable economic conditions create a conducive environment for market growth.In summary, the Psychotic Disorders market in France is experiencing growth and development driven by evolving customer preferences, local special circumstances, and underlying macroeconomic factors. The market is witnessing a shift towards personalized treatment options, non-pharmacological interventions, and early intervention strategies. The country's well-developed healthcare system, government initiatives, and stable economy contribute to the market's expansion.

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Despite what some may think, mental health problems are common in the United States and around the world. Mental health issues, much like other health issues, can be mild, but can also be life altering, affecting the emotional, social, and psychological well-being of the person. Common types of mental illness include mood disorders, anxiety disorders, eating disorders, and personality disorders. Although symptoms of mental illness differ depending on the type of illness and seriousness of the problem, common symptoms of mental health issues include changes in sleeping and eating habits, social withdrawal, feelings of hopelessness, anger, and prolonged sadness, suicidal thoughts, and substance abuse. In 2022, it was estimated that around 36 percent of those in the U.S. aged 18 to 25 years and 29 percent of those aged 26 to 49 years suffered from some form of mental illness in the past year.